SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: billkirn who wrote (753)5/15/1997 11:08:00 PM
From: John Metcalf   of 6136
 
Bill, AGPH breached $74 on an intraday basis today. Is this your short covering signal, or are you looking for a close above $74?

Also, since you mentioned Roche, there are some events to watch:

1) European approvals have been filed. Roche will market in Europe, paying royalties. As I understand it, ROC.Z will pay royalties on its own Saquinivir, if sales exceed Viracept's. So European launch will be immediately accretive to earnings.

2) Roche just made a world-wide research arrangement with Alanex, which Agouron has acquired. They're approaching the point where not buying AGPH (or a substantial equity in it) will cost more than buying it.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News